2017 Fiscal Year Final Research Report
The development of a HuR-targeted drug as a new therapeutics agent
| Project/Area Number |
15K20822
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
Pathobiological dentistry/Dental radiology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | HuR / Oral cancer / ARE-mRNA / screening / approved drug library |
|---|
| Outline of Final Research Achievements |
we screened 1570 compounds in the approved drug library by differential scanning fluorimetry (DSF) to discover a HuR-targeted compound. Of them, suramin, an anti-trypanosomal drug, binds specifically to HuR on surface plasmon resonance (SPR). We confirmed that suramin significantly decreased ARE-mRNA and protein expression. The mRNAs were destabilized by suramin. Furthermore, the motile and invasive activities of a tongue carcinoma cell line, HSC-3, treated with suramin were markedly lower than those of control cells. The above findings suggest that suramin binds to HuR and inhibits its function. We also showed that the anticancer effects of suramin were caused by the inhibition of HuR function, indicating its potential as a novel therapeutic agent in the treatment of oral cancer.
|
| Free Research Field |
Oral cancer
|
